While the World Health Organization included Epstein-Barr virus (EBV)-positive diffuse large B-cell lymphoma (DLBCL) as a provisional entity of a lymphoma occurring in older individuals without any known immunodeficiency in 2008, it has since been recognized that this entity may occur in younger individuals. As a result, the 2016 revision has substituted the modifier "elderly" with "not otherwise specified" (NOS). The NOS highlights that there are more specific entities with neoplastic EBV-positive large B cells such as lymphomatoid granulomatosis. Diagnosis requires that there be no other cause of immunodeficiency and that other more specific entities with neoplastic EBV plus large B cells be excluded. We present the case of an 81-year-old woman hospitalized for generalized weakness, increasing confusion, unexplained weight loss, and intermittent fevers. Examination showed lymphadenopathy, lesions in the liver and small intestine, and a very high EBV viral load. She experienced a rapid demise and at autopsy was found to have EBV+ DLBCL, NOS.
While the World Health Organization included Epstein-Barr virus (EBV)-positive diffuse large B-cell lymphoma (DLBCL) as a provisional entity of a lymphoma occurring in older individuals without any known immunodeficiency in 2008, it has since been recognized that this entity may occur in younger individuals. As a result, the 2016 revision has substituted the modifier "elderly" with "not otherwise specified" (NOS). The NOS highlights that there are more specific entities with neoplastic EBV-positive large B cells such as lymphomatoid granulomatosis. Diagnosis requires that there be no other cause of immunodeficiency and that other more specific entities with neoplastic EBV plus large B cells be excluded. We present the case of an 81-year-old woman hospitalized for generalized weakness, increasing confusion, unexplained weight loss, and intermittent fevers. Examination showed lymphadenopathy, lesions in the liver and small intestine, and a very high EBV viral load. She experienced a rapid demise and at autopsy was found to have EBV+ DLBCL, NOS.
CASE PRESENTATION
An 81-year-old white woman presented to the emergency department after increased confusion and generalized weakness followed by an unwitnessed fall at home. She had a 20-pound weight loss over 2 months and intermittent fevers during the same time. Her past medical history was notable for a cerebrovascular accident 4 years prior, vascular dementia, diabetes mellitus type 2, paroxysmal atrial fi brillation, hyperlipidemia, gastroesophageal refl ux disease, and hypothyroidism. On admission, she had a temperature of 97.7°, blood pressure of 118/58 mm Hg, and heart rate of 100 beats/min. Her blood work showed a white blood cell count of 3.2 K/μL and a platelet count of 94 K/μL. Cultures and testing for HIV, hepatitis B, hepatitis C, cytomegalovirus, and parvovirus B19 were all negative. Her Epstein-Barr virus (EBV) viral load was >1,100,000 IU/mL by polymerase chain reaction. A computed tomography (CT) scan of the chest, abdomen, and pelvis found multiple prominent lymph nodes. Th e abdominal ultrasound showed thickening of the gallbladder, but no overt cholecystitis. A CT of the head was negative. Th e patient was started on broad-spectrum antibiotics for continued fever and leukopenia, but treatment was discontinued because no source of infection was identifi ed. Th e patient continued to decline and did not desire invasive life-sustaining measures; thus, comfort measures were started on hospital day 13, and she died shortly thereafter. An autopsy was performed and revealed diff use lymphadenopathy, especially in the paratracheal, periaortic, and peripancreatic areas. Microscopically, the lymph nodes showed massive eff acement with infi ltrates of large lymphoid cells (Figure 1a ). Th ese cells had scant to moderate amounts of basophilic cytoplasm, large irregular nuclei, and prominent nucleoli, and they focally extended through the capsules into the surrounding adipose tissue and into lymphatic vessels. Similar collections of atypical lymphoid cells were found in the lung interstitium, liver portal tracts and sinusoids, splenic white and red pulp, gastric submucosal vessels, epicardium, left atrium, and bone marrow. Immunohistochemistry testing showed that the tumor was positive for CD20 (Figure 1b) , MUM1, and BCL2, had a proliferative index (Ki-67) of 60%, and was negative for BCL6, CD3, cMYC, and CD10. In situ hybridization for EBV (EBER-ISH) was positive (Figure 1c) . Th e morphologic and immunophenotypic results represent a diff use large B-cell lymphoma (DLBCL), post-germinal center type, consistent with EBV-positive DLBCL, not otherwise specifi ed (NOS).
DISCUSSION
EBV is a double-stranded, enveloped virus that belongs to the Herpesviridae family. EBV shows tropism for epithelial cells as well as B-cell lymphocytes (1, 2) . Almost all humans are exposed to EBV at some point in their life, and after exposure EBV confers a lifelong latency. Th is can cause problems in the aging population. With age, the immune system enters a state of immunosenescence characterized by a decrease in the diversity of B cells, causing an in vivo clonal expansion. At the same time, T-cell lymphocytes are decreasing in number with a decline in naive T cells and T-cell receptor diversity (3). Th ese changes result in more circulating cells with EBV-specifi c receptors. Cells with latent EBV infection express EBER protein and may express other proteins such as EBNA and LMP proteins (3) . EBV also induces the NFκB pathway, which may be required for survival of the cells in DLBCL (2). Tissues, EBV+ DLBCL, NOS is diagnosed in apparent immunocompetent patients, usually over 50 years of age (4). Th is lymphoma was a provisional entity in the 2008 World Health Organization classifi cation, entitled EBV+ DLBCL of the elderly, but the "elderly" designation was substituted with "not otherwise specifi ed" with the recognition that this entity occurs in younger patients (4, 5) . Th e NOS designation highlights that the lymphoma must be excluded from more specifi c entities with neoplastic EBV-positive large B cells, such as lymphomatoid granulomatosis, DLBCL associated with chronic infl ammation, and the newly designated entity EBV-positive mucocutaneous ulcer (4).
EBV-positive DLBCL accounts for 8% to 15% of DLBCL in the Asian population (2-4). Within Western populations, the percentage is lower (<5%) (2, 3) . Some studies found a median age of 71 and a slight male predominance. Lymph node involvement is seen in about 70% of cases. Microscopically, the lymph node architecture is eff aced and consists of a uniform population of large cells with extensive necrosis, mitoses, and apoptoses. If minimal to no reactive component (small lymphocytes, plasma cells, or histiocytes) is seen, the disease is subclassifi ed as monomorphic. Th e disease is classifi ed as polymorphic if a reactive component is present (2, 3) . Th is morphologic subclassifi cation has not been shown to have prognostic implications (3) .
Th e immunohistochemical profi le is generally positive for B-cell markers CD20, CD19, CD79a, and PAX-5. CD10 and BCL6 are usually negative, while MUM1 is commonly positive. Cases with immunoblastic or plasmablastic features may lack CD20 expression (5). In situ hybridization for EBER is positive and is considered the most important test in diagnosis, with the highest diagnostic sensitivity (2) .
EBV+ DLBCL has a poor response to treatment, so rapid detection is a necessity. Detection relies on clinical suspicion and looking for EBV in every case of DLBCL. Th e prognosis of EBV+ DLBCL is worse than that of EBV-negative tumors, with a median survival of 2 years (5, 6). Prognosis is worse in patients 70 years or older and in those with B symptoms. Currently, there is no uniformly accepted treatment for EBV+ DLBCL beyond the current standard therapy for DLBCL (2, 6) . Th e standard treatment for DLBCL is the combination of rituximab, a chimeric anti-CD20 monoclonal antibody, with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) (2) . Some studies suggest improved prognosis with more intensive regimens, such as combination rituximab, etoposide, prednisolone, vincristine, cyclophosphamide, and doxorubicin (R-EPOCH) (7) . 
